90022 Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 

Contact Person: Ombretta Salvucci, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W264, Rockville, 

Maryland 20850, 240–276–7286, salvucco@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Institutional 

Training and Education Study Section (F). 

Date: February 11–12, 2025. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W234, Rockville, Maryland 20850. 

Meeting Format: Virtual Meeting. 

Contact Person: Adriana Stoica, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W234, Rockville, Maryland 20850, 

240–276–6368, Stoicaa2@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI SPORE 

(P50) Review SEP–III. 

Date: February 25–26, 2025. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Cancer Institute at 

Shady Grove, 9609 Medical Center Drive, 

Room 7W514, Rockville, Maryland 20850. 

Meeting Format: Virtual Meeting. 

Contact Person: Wlodek Lopaczynski, 

M.D., Ph.D., Assistant Director, Office of the 

Director, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W514, Rockville, 

Maryland 20850, 240–276–6340, lopacw@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI U54– 

SPORE–SEP II. 

Date: March 5–6, 2025. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Cancer Institute at 

Shady Grove, 9609 Medical Center Drive, 

Room 7W522, Rockville, Maryland 20850. 

Meeting Format: Virtual Meeting. 

Contact Person: Klaus B. Piontek, Ph.D., 

Chief, Research Programs Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W522, Rockville, Maryland 

20850, 240–276–5413, klaus.piontek@

nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.392, Cancer 

Construction; 93.393, Cancer Cause and 

Prevention Research; 93.394, Cancer 

Detection and Diagnosis Research; 

93.395, Cancer Treatment Research; 

93.396, Cancer Biology Research; 

93.397, Cancer Centers Support; 93.398, 

Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of 

Health, HHS) 

Dated: November 8, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26497 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Biological Chemistry and Biophysics. 

Date: December 2, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Razvan Liviu Cornea, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 904L, 

Bethesda, MD 20892, (301) 480–1955, 

cornearl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Fogarty HIV Research Training Program for 

Low- and Middle-Income Country 

Institutions. 

Date: December 5–6, 2024. 

Time: 12:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ross D. Shonat, MS, Ph.D., 

BS Division Director, DPPS Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4100, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

2786, ross.shonat@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–MH– 

25–140: Streamlining mental health 

interventions for youth living with HIV in 

low and middle-income countries. 

Date: December 6, 2024. 

Time: 10:00 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elia E. Ortenberg, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

Bethesda, MD 20892, 301–827–7189, 

femiaee@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: HIV/AIDS Interventions and 

Population and Public Health Approaches. 

Date: December 6, 2024. 

Time: 1:45 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elia E. Ortenberg, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

Bethesda, MD 20892, 301–827–7189, 

femiaee@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 7, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26427 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Novel and Exceptional 

Technology and Research Advisory 

Committee. 

The meeting will be held as a virtual 

meeting and will be open to the public 

as indicated below. Individuals who 

plan to view the virtual meeting and 

need special assistance or other 

reasonable accommodations to view the 

meeting should notify the Contact 

Person listed below in advance of the 

meeting. The meeting will be videocast 

and can be accessed from the NIH 

Videocasting and Podcasting website 

(https://videocast.nih.gov/). 

Name of Committee: Novel and 

Exceptional Technology and Research 

Advisory Committee. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 90023 

Date: December 3, 2024. 

Time: 11:00 a.m.–12:00 p.m. 

Agenda: The Novel and Exceptional 

Technology and Research Advisory 

Committee (NExTRAC) will receive an 

update from the Working Group on Engaging 

the Public as Partners in Clinical Research 

and discuss the next steps regarding the 

current charge to the committee, delivered in 

August 2023. 

Address: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Suite 

630, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Meeting Access Link: Virtual Meeting Link 

will be available at https://osp.od.nih.gov/ 

policies/novel-and-exceptional-technologyand-research-advisory-committeenextrac#tab4/. 

Contact Person: Jessica Tucker, Ph.D., 

Office of Science Policy, National Institutes 

of Health, 6705 Rockledge Drive, Suite 630, 

Bethesda, MD 20892, 301–496–9838, 

SciencePolicy@od.nih.gov. 

Any interested person may file written 

comments by forwarding the statement to the 

Contact Person listed on this notice at least 

two business days prior to the meeting date. 

The statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. Other 

than name and contact information, please 

do not include any personally identifiable 

information or any information that you do 

not wish to make public. Proprietary, 

classified, confidential, or sensitive 

information should not be included in your 

comments. Please note that any comments 

NIH receives may be posted unredacted to 

the Office of Science Policy website. 

Information is also available on the NIH 

Office of Science Policy website: https://

osp.od.nih.gov/policies/novel-andexceptional-technology-and-researchadvisory-committee-nextrac#tab4, where an 

agenda, link to the webcast meeting, and any 

additional information for the meeting will 

be posted when available. Materials for this 

meeting will be posted prior to the meeting. 

Please check this website for updates. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: November 7, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26426 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Arthritis and 

Musculoskeletal and Skin Diseases 

Advisory Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The open 

session will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (https://

videocast.nih.gov/). 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Arthritis and 

Musculoskeletal and Skin Diseases Advisory 

Council. 

Date: January 28, 2025. 

Open: 9:30 a.m. to 3:00 p.m. 

Agenda: Call to Order; NIAMS Director’s 

Report and Discussion; Open Discussion. 

Address: National Institutes of Health, 31 

Center Street, Bethesda, MD 20892, (Virtual 

Meeting). 

Closed: 3:15 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Address: National Institutes of Health, 31 

Center Street, Bethesda, MD 20892, Virtual 

Meeting. 

Contact Person: Darren D. Sledjeski, Ph.D., 

Director, Division of Extramural Activities 

(DEA), National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 6701 

Democracy Blvd., Bethesda, MD 20892, (301) 

451–7766, darren.sledjeski@nih.gov. 

Any interested person may file 

written comments with the committee 

by forwarding the statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/ 

about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All 

visitor vehicles, including taxicabs, 

hotel, and airport shuttles will be 

inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal 

facility will be asked to show one form 

of identification (for example, a 

government-issued photo ID, driver’s 

license, or passport) and to state the 

purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.niams.nih.gov/about/workinggroups/advisory-council, where an 

agenda and any additional information 

for the meeting will be posted when 

available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: November 8, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–26479 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government Owned Inventions 

Available for Licensing or 

Collaboration: Machine Learning 

Model for the Prioritization of Cancer 

Neoepitopes 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

giving notice of licensing and 

collaboration opportunities for the 

inventions listed below, which are 

owned by an agency of the U.S. 

Government and are available for 

license and collaboration in the U.S. to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to a collaboration 

opportunity should be directed to: Aida 

Cremesti, Senior Technology Transfer 

Manager, NCI, Technology Transfer 

Center, Email: aida.cremesti@nih.gov or 

Phone: 240–276–6641. Inquiries related 


ddrumheller on DSK120RN23PROD with NOTICES1